Mr S. is a 62-year-old restaurant owner who has had
|
|
- Clarissa Fowler
- 5 years ago
- Views:
Transcription
1 Brief Review: From Bench to Bedside Endothelial Progenitor Cells New Hope for a Broken Heart Paul E. Szmitko, BSc; Paul W.M. Fedak, MD; Richard D. Weisel, MD; Duncan J. Stewart, MD; Michael J.B. Kutryk, MD, PhD; Subodh Verma, MD, PhD Mr S. is a 62-year-old restaurant owner who has had recurrent stable angina that has not improved despite maximal medical therapy and an earlier coronary bypass. On angiography, Mr S. has diffusely diseased coronary vessels and is no longer considered a candidate for further direct revascularization. An alternative treatment strategy for revascularizing ischemic tissue is therefore required. One potential strategy, therapeutic neovascularization, aims to promote the formation of natural bypasses or collaterals within the ischemic tissue by harvesting the potential of endothelial progenitor cells (EPCs). This From Bench to Bedside article will explore the current concept of an EPC, the role EPCs play in neovascularization, the strategies used to maximize EPC number and function, the experimental and clinical evidence supporting EPC utility, and the future direction of EPC research. See p 2995 What Are EPCs? Progenitor cells are primitive bone marrow (BM) cells that have the capacity to proliferate, migrate, and differentiate into various mature cell types. EPCs, in particular, possess the ability to mature into the cells that line the lumen of blood vessels. 1 The first evidence indicating the presence of EPCs in the adult circulation emerged when mononuclear blood cells from healthy human volunteers were shown to acquire an endothelial cell like phenotype in vitro and to incorporate into capillaries in vivo. 2 These putative EPCs were characterized via expression of CD34 and vascular endothelial growth factor receptor-2 (VEGFR-2), 2 antigens shared by embryonic endothelial progenitors, and hematopoietic stem cells (HSCs). Subsequent studies confirmed that CD34 cells isolated from BM or umbilical cord blood also had the capacity to differentiate into mature endothelial cells. 3 5 However, both CD34 and VEGFR-2 are expressed on mature endothelial cells. 6 Thus, the search for more unique EPC markers continued. In addition to CD34, early hematopoietic progenitor cells express CD133 (AC133), which is not expressed after differentiation. 6,7 Using CD133 expression to define a very early subset of progenitor cells, Peichev et al 8 isolated a VEGFR- 2 /CD133 /CD34 subpopulation of cells able to differentiate into mature endothelial cells. More recently, hematopoietic progenitor cells that express CD34 and fibroblast growth factor receptor-1, or coexpress CD34, CD133, and VEGFR-3, have been shown to behave as EPCs. 9,10 Currently, most studies that estimate the number of EPCs in the circulation measure the number of CD34 /VEGFR-2 or CD133 /VEGFR-2 cells. 11,12 However, the expression of CD34 does not appear to be an absolute requirement for EPC identification. Populations of CD34 HSCs and CD34 / CD133 /VEGFR-2 mesenchymal stem cells have been demonstrated to give rise to EPCs and generate mature endothelial cells. 13,14 Thus, the lineage and exact phenotype of EPCs are not yet known. What Roles Do EPCs Have in the Adult? The endothelium is a single-cell lining covering the internal surface of blood vessels, cardiac valves, and numerous body cavities that plays an important role in thrombogenicity, anticoagulation, leukocyte and platelet adherence, and vessel wall contraction and relaxation. 15 Endothelial dysfunction predisposes to vasoconstriction, thrombosis, and atherosclerosis. 16 EPCs may play an important role in endothelium maintenance, being implicated in both reendothelialization and neovascularization. Restoration of the Endothelial Lining The physiological significance of EPC mobilization was illustrated in studies in which the thoracic aortae of adult dogs that underwent BM transplantation were implanted with Dacron grafts. 17 After 3 months, the grafts were retrieved and found to be colonized with CD34 endothelial cells of donor origin, suggesting that endothelialization arose exclusively from BM-mobilized EPCs. In humans, the surfaces of left ventricular assist devices were found to be colonized with CD133 /VEGFR-2 cells. 8 Together, these studies suggest the existence of a population of EPCs in the peripheral circulation that contributes to rapid endothelialization to prevent thrombotic complications. From the Divisions of Cardiology (D.J.S., M.J.B.K.) and Cardiac Surgery (P.E.S., P.W.M.F., R.D.W., S.V.), University of Toronto, Toronto, Ontario, Canada. Correspondence to Subodh Verma, MD, PhD, Division of Cardiac Surgery, Toronto General Hospital, 14EN-215, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4. subodh.verma@sympatico.ca (Circulation. 2003;107: ) 2003 American Heart Association, Inc. Circulation is available at DOI: /01.CIR A 3093
2 3094 Circulation June 24, 2003 Figure 1. EPCs facilitate neovascularization and angiogenesis. Mobilization of EPCs from BM is enhanced by VEGF, angiopoietin-1, fibroblast growth factor (FGF), GM-CSF, MMP-9 activity, pharmacological agents such as statins, and erythropoietin (EPO). The mobilization and incorporation of BM-derived EPCs has recently been shown to modulate reendothelialization at sites of endothelial cell damage. 18,19 Both studies induced carotid artery endothelium injury and subsequently identified the incorporation of BM-derived endothelial cells at the site of injury. Thus, by restoring an intact endothelium, EPCs may participate in the maintenance of vascular homeostasis. EPCs and Neovascularization In the past, the vascularization of adult tissue was considered to occur via angiogenesis, the sprouting of new vessels from existing ones. It relies on the proliferation, migration, and remodeling of fully differentiated endothelial cells. 20,21 However, with the discovery of circulating EPCs, it is currently believed that a combination of angiogenesis and a modified type of vasculogenesis contributes to neovascularization (Figure 1). Vasculogenesis refers to the formation of blood vessels de novo out of primitive EPCs during embryological development. 6,21 With evidence suggesting EPC incorporation into the vasculature, EPC-dependent neovascularization in adults may represent a third means of blood vessel formation, paralleling developmental vasculogenesis in the embryo. EPCs may serve as the substrate for new vessel formation and simultaneously exert a paracrine effect to promote angiogenesis.
3 Szmitko et al Endothelial Progenitor Cells 3095 Evidence for the potential of EPCs to participate in new blood vessel formation emerged from studies that demonstrated the formation of capillary-like structures from isolated HSCs or ex vivo expanded EPCs. 3,22 The contribution of BM-derived cells to neovascularization, after ischemic injury in vivo, was shown in experiments using labeled populations of stem cells to reconstitute lethally irradiated mice. Jackson et al 23 demonstrated the incorporation of labeled endothelial cells in regions of myocardial infarction. Using a mouse retinopathy model, Grant et al 24 demonstrated that the recruitment of endothelial precursors to sites of ischemic injury plays a significant role in neovascularization. Using a single green fluorescent protein (GFP) expressing stem cell, the group successfully reconstituted lethally irradiated mice. Three weeks after photocoagulation of the retinal vasculature to induce retinopathy, the damaged retinal vessels were replaced with a new, developing GFP capillary network. BM-derived EPCs also contribute to neovascularization during the newborn period, are present in corpus luteal and endometrial neovasculature after inductive ovulation, and are incorporated into vessels during wound healing. 25,26 However, pathological tumor angiogenesis also depends on the recruitment of hematopoietic and circulating endothelial precursor cells. 27 Thus, blockade of EPC migration may serve as a new target for antiangiogenesis therapy. 28 If EPC-mediated neovascularization could be medically influenced and optimized to restore sufficient blood flow to ischemic areas, therapeutic revascularization would be possible. But before the therapeutic potential of cell-based therapies is realized, the mechanisms underlying EPC differentiation, mobilization, and recruitment must be identified. What Factors Influence the Number of EPCs in the Circulation? The majority of EPCs reside in the BM in close association with HSCs and BM stromal cells that provide the microenvironment for hematopoiesis. 1 Within the BM, the progenitor cells are at different stages of differentiation. Under steadystate physiological conditions, EPCs represent only 0.01% of circulating mononuclear cells. 29 For the progenitor cells to leave the BM, mobilization, which is a dissociation of the contact between the stromal cell and the EPC, is required. 6 This process is termed recruitment. EPC Recruitment and Mobilization Endogenous stimuli such as tissue ischemia as well as exogenous cytokine therapy have been demonstrated to promote the mobilization of EPCs. The development of regional ischemia in both rabbits and mice resulted in an increase in the number of circulating EPCs. 30 Similarly, EPCs were mobilized in patients with vascular trauma or acute myocardial infarction (AMI). 11,31 Flow cytometry revealed that EPC counts significantly increased in AMI patients compared with control subjects, an increase that was positively correlated to the elevated plasma levels of vascular endothelial growth factor (VEGF) in these patients. 31 This capability of activating the endogenous regenerative capacity of EPCs is most likely mediated by chemokine and cytokine release. Several studies have shown that the angiogenic growth factor VEGF promotes mobilization of EPCs and their incorporation into sites of neovascularization. 26,32 35 VEGF promotes angiogenesis by inducing proliferation, differentiation, and chemotaxis of endothelial cells. 36 It is essential for hematopoiesis and angiogenesis as illustrated by the death of mice in utero that have a single VEGF allele. 37 Multiple isoforms of VEGF are secreted VEGF 165 being the most abundant that exert their biological effects through interaction with 2 tyrosine kinase receptors, VEGFR-1 and VEGFR Both of these receptors are expressed on HSCs and EPCs. The secretion of VEGF by HSCs and other cells in the BM compartment may induce EPC proliferation, BM vascular remodeling, and modulation of adhesion molecule expression, promoting EPC migration from the BM. 38 After VEGF administration in mice, EPCs were significantly increased in the circulation and displayed enhanced proliferative and migratory activity. 32 In patients with lower limb ischemia who received VEGF gene transfer, there was an overall increase by 200% in circulating EPCs. 34 These results suggest that VEGF overexpression can mobilize EPCs in humans. In addition to VEGF, other angiogenic growth factors, including angiopoietin-1, fibroblast growth factor, and stromal cell derived growth factor-1 (SDF-1), stimulate EPC mobilization and recruitment. 26,35,39 Placental growth factor, a member of the VEGF family, was shown to stimulate collateral vessel formation in ischemic heart and limbs by acting via VEGFR-1 and inducing the recruitment of BM-derived EPCs. 40,41 In addition to the direct effects of VEGF on EPC mobilization, VEGF can also induce the release of hematopoietic growth factors, such as granulocytemacrophage colony-stimulating factor (GM-CSF) by BM endothelial cells. 42 Several chemokines and cytokines have been shown to promote the mobilization of EPCs. In mice, exogenously administered GM-CSF specifically mobilized EPCs that contributed to improved vascularization in ischemic hindlimbs. 30 Similarly, a clinical trial administering GM-CSF to patients with extensive coronary artery disease (CAD) documented an overall improvement in myocardial collateral flow. 43 Although not determined, EPC recruitment to the myocardium may have contributed to this favorable outcome. Granulocyte colony stimulating factor (G-CSF), like GM-CSF, has been shown to increase the number of CD34 cells that could stimulate neovascularization in regions of ischemic myocardium. 4 Injection of the chemokine stem cell factor (SCF, skitl) has also been shown to mobilize stem cells. 6 The recruitment of progenitor cells from the BM appears to require matrix metalloproteinase-9 (MMP-9) activity. 44 MMP-9 / mice have impaired stem cell mobilization and MMP inhibitors effectively block EPC mobilization. MMP-9 activity causes the shedding of SCF, which favors recruitment of c-kit positive progenitors, such as EPCs, from the BM. The release of stem cell active cytokines by metalloproteinase activity promotes the motility of otherwise quiescent EPCs. 29 The mechanism by which placental growth factor recruits BM-derived progenitor cells was also demonstrated to involve upregulation of MMP-9 activity, meditating SCF
4 3096 Circulation June 24, 2003 release. 41 Once recruited and mobilized, the EPCs must home to and differentiate at the site of endothelialization. EPC Homing and Differentiation The same factors responsible for mobilization may also play a role in EPC migration and incorporation. Increased expression of VEGF, after either vascular injury or exogenous delivery, recruits EPCs. EPC migration to the site of vascular injury paralleled plasma VEGF elevation. 11 Similarly, implantation of either a VEGF-loaded Matrigel plug or a VEGF pellet stimulated neovessel formation at the implantation site with a significant contribution by EPCs. 38,45 This suggests that EPCs were drawn to the site of implantation by VEGF. SDF-1 may also contribute to EPC homing. SDF-1, which is elevated after myocardial infarction, binds to the chemokine receptor CXCR-4, which is highly expressed on EPCs. 39,46,47 To support homing to and incorporation into sites of vascular injury, the adhesiveness of EPCs may be altered. After human EPCs were exposed to simvastatin, the expression of integrin subunits 5 1 and v 5 was upregulated. 18 Both 5 1 and v 5 are known to play a role in angiogenesis. 48 These simvastatin-treated EPCs displayed increased incorporation into the neoendothelium of balloon-injured carotid arteries, which was abrogated on integrin receptor blockade. 18 These results suggest that homing to and incorporation into foci of ischemic or vascular injury is determined not only by the number of circulating EPCs but also by the adhesiveness of EPCs, which changes during maturation. The mechanisms mediating EPC homing and differentiation are just beginning to be elucidated. Future work understanding these pathways may lead to new targets that can be exploited to maximize the efficiency of EPC-mediated neovascularization. Influence of Cardiovascular Risk Factors on EPCs EPC characterization in CAD patients was conducted by Vasa et al. 12 The study reported an inverse correlation between the number of cardiovascular risk factors and the number and migratory activity of EPCs. Smoking was determined to be the major independent predictor for reduced EPC levels, whereas impairment of EPC migration was mainly influenced by hypertension. The mechanisms by which atherosclerotic risk factors reduce EPC number and function remain to be determined. However, Vasa et al 12 speculate that these mechanisms may involve increased apoptosis of EPCs or interference with pathways regulating EPC differentiation and mobilization. Recently, it has been suggested that the levels of EPCs may serve as a surrogate biological marker for vascular function and cumulative cardiovascular risk. 49 What Pharmacological Strategies Augment EPC Mobilization and Differentiation? Aside from the use of exogenously administered growth factors, cytokines, or chemokines, HMG-CoA reductase inhibitors or statins have been shown to enhance EPC mobilization and function. Statins possess favorable effects such as endothelial function improvement independent of cholesterol reduction. 50 Dimmeler et al 51 and Llevadot et al 52 both demonstrated that statins increased EPC differentiation in vitro and enhanced mobilization of EPCs in vivo. These favorable effects were likely mediated via the phosphatidyl inositol 3-kinase/Akt pathway, a pathway also utilized by angiogenic growth factors to influence HSC differentiation. 53 Treatment with statins promoted angiogenesis in normocholesterolemic animals and resulted in the accumulation of marrow-derived endothelial cells at sites of corneal neovascularization. 52,54 The ability of statins to mobilize EPCs is further illustrated by the 3-fold increase in circulating EPCs in stable CAD patients after 4 weeks of atorvastatin treatment. 55 Thus, the potential of statins to increase the number of circulating EPCs that can participate in repair after ischemic injury may contribute to the mechanism by which statins enhance coronary blood flow in patients with stable CAD. 56 Statin therapy has also been shown to accelerate reendothelialization after vascular injury. 18,19 Statins increased EPC mobilization and their incorporation into sites of damaged endothelium, minimizing the development of intimal hyperplasia. Modulation of integrin receptor expression was also induced by statin therapy, altering the adhesiveness of cells, which may promote EPC homing. 18 Thus, statins may limit neointimal formation and ultimately the occlusion of diseased vessels in part by enhancing the mobilization and homing of EPCs after vascular injury. What Evidence Is There That EPCs Are Useful for Regeneration and Repair? With the identification of EPCs as important players in adult neovascularization, several studies have attempted to utilize EPCs to restore blood flow to ischemic tissue. Most have involved the transplantation of ex vivo expanded EPCs. EPC Transplantation for Peripheral Ischemia The transplantation of EPCs significantly improved blood flow recovery and capillary density in several animal hindlimb ischemia models. Kalka et al 57 demonstrated that ex vivo expanded human EPCs (hepcs) could be used successfully to promote neovascularization of ischemic hindlimbs in athymic nude mice. Mice receiving hepcs had increased capillary density and significantly improved blood flow in the ischemic limb after transplantation. The perfusion in the hepctransplanted mice was sufficient to significantly increase the chance of successful limb salvage. Subsequent studies showed that autologous BM cell transplantation in a rat ischemic hindlimb model and BM mononuclear cell transplantation in a rabbit model of hindlimb ischemia were able to improve collateral vessel formation and blood perfusion in the ischemic limb. 58,59 Furthermore, EPC transplantation induces blood flow recovery in the ischemic hindlimbs of both diabetic mice and rats, suggesting that EPC-mediated neovascularization can still occur under disease conditions and thus be applied as a therapeutic treatment in the patients who would benefit most. 60,61 EPC Transplantation for Ischemic Myocardium Just as progenitor cell transplantation restored blood flow to ischemic hindlimbs, EPC transplantation after myocardial infarction also induced neovascularization. Kawamoto et al 62 demonstrated that transplanted, ex vivo expanded hepcs had
5 Szmitko et al Endothelial Progenitor Cells 3097 a favorable impact on the preservation of left ventricular function. After the induction of myocardial ischemia, labeled hepcs were injected intravenously. The hepcs were shown to accumulate in the ischemic area and to participate in myocardial neovascularization. Echocardiography revealed ventricular dimensions that were significantly smaller and fractional shortening that was significantly greater in the hepc transplant. The transplant group also had less ventricular scarring and better-preserved wall motion. Similar findings were documented by Kocher et al 4 after the transplantation of G-CSF mobilized CD34 human cells containing both HSCs and EPCs. Transplantation was shown to improve myocardial function, prevent cardiomyocyte apoptosis, and limit myocardial remodeling. Neovascularization was observed both within the myocardial infarct and along the infarct border. However, endothelial cells of human origin tended to localize at the infarct core, whereas rat-derived endothelial cells contributed to new vessel formation at the infarct border. This suggests that BM-derived progenitor cells may directly contribute to in situ vessel formation in the core region and stimulate angiogenic sprouting from existing endothelium at the infarct border. A subsequent study using a swine myocardial infarction model showed that the implantation of BM-derived mononuclear cells, cells that actively differentiated to endothelial cells in vitro, improved regional cardiac function. 63 Three weeks after implantation, regional blood flow, capillary density, and the number of visible collateral vessels were significantly higher in transplant recipients compared with controls, with no malignant ventricular arrhythmias or bone formation by osteoblasts detected. Kamihata et al 63 conclude that BM implantation represents a novel and safe strategy to achieve therapeutic angiogenesis. The beneficial effects are likely mediated by the ability of the transplanted cells to become incorporated into new vessels and to promote angiogenesis through angiogenic ligand secretion. However, a recent study has shown that EPCs can transdifferentiate into functionally active cardiomyocytes and thus may potentially assist with cardiomyocyte regeneration after ischemia. 64 EPC Transplantation in Humans Initial results from clinical trials assessing the safety and feasibility of autologous progenitor cell transplantation are rather promising. The Therapeutic Angiogenesis using Cell Transplantation Study involved autologous implantation of BM mononuclear cells in patients with ischemic limbs as a consequence of peripheral arterial disease. 65 At 4 weeks after the random injection of BM mononuclear cells into the gastrocnemius of one leg and peripheral blood mononuclear cells into the other leg as a control in patients with bilateral leg ischemia, various outcomes were measured. Legs into which the BM mononuclear cells were injected had a significantly improved ankle-brachial index, an improved transcutaneous oxygen pressure, a significant reduction in rest pain, and an increase in pain-free walking time. Improvements were sustained at 24 weeks with no serious complications. These promising results were attributed to the ability of marrow cells to initiate therapeutic angiogenesis by supplying both EPCs and angiogenic factors. Two recent studies demonstrate that intracoronary infusion of autologous progenitor cells after AMI appears to be safe and effective in limiting postinfarction remodeling processes. The Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE- AMI) Trial was established to assess the safety and feasibility of autologous progenitor cell transplantation in patients with ischemic heart disease. 66 Twenty patients with reperfused AMI were randomly assigned to receive an infusion of either BM-derived or circulating blood derived progenitor cells into the infarct artery. At 4 months, transplantation of progenitor cells resulted in a significant increase in global left ventricular ejection fraction, improved regional wall motion in the infarct zone, reduced end-systolic left ventricular volumes, and increased myocardial viability in the infarct zone compared with a nonrandomized matched reference group. No differences were detected between the bloodderived and BM-derived progenitor cell groups, and no malignant arrhythmias or inflammatory reactions were observed. A second controlled clinical trial analyzed 10 patients with AMI who were treated by intracoronary transplantation of autologous mononuclear BM cells in addition to standard therapy. 67 After 3 months, the group receiving cell transplantation showed a significant decrease in infarct region size and a significant increase in infarcted wall movement velocity compared with AMI patients treated with standard therapy alone. The transplant group also showed significant improvements in stroke volume index, left ventricular end-systolic volume, contractility, and perfusion of the infarct region. Taken together, the results of these 2 studies suggest that intracoronary infusion of progenitor cells can improve outcome after AMI (Figure 2). However, the results from larger-scale, randomized trials are required before the longterm clinical outcome of AMI patients receiving cell transplantation is known. What Does the Future Hold? With the promising results from both animal studies and early human clinical trials, the future for therapeutic neovascularization mediated by EPC transplantation appears bright. Since the discovery of EPCs in the adult circulation 6 years ago, a great deal of information related to the mechanisms controlling EPC recruitment, mobilization, homing, differentiation, and function has been obtained. However, more research in these molecular and biochemical pathways is required to shed light on how biological conditions may be optimized to increase neovascularization in patients with CAD or peripheral arterial disease. Future multipronged approaches that combine EPC transplantation with growth factor, cytokine, and pharmacological treatments may improve the therapeutic outcome in patients. One potential strategy may involve genetically modifying EPCs before transplantation Iwaguro et al 69 demonstrated that gene transfer of vectors encoding VEGF into EPCs ex vivo and injection of these modified EPCs into the ischemic hindlimbs of mice significantly increased neovascularization and hindlimb perfusion compared with mice transplanted with nontransduced EPCs. These VEGF-transduced EPCs displayed enhanced proliferation, adhesion, and incorporation and may operate not only
6 3098 Circulation June 24, 2003 Figure 2. Therapeutic potential of EPCs. Intracoronary infusion of EPCs in patients with AMI may have the potential to restore myocardial function to the damaged area. EPC transplantation increases left ventricular ejection fraction (LVEF), coronary blood flow reserve, and myocardial viability and decreases left ventricular end-systolic volume (LVESV). 66 as substrate for new vessels but also as VEGF secretors promoting the migration, proliferation, and remodeling of differentiated endothelial cells residing in the target ischemic tissue. Thus, by enhancing the angiogenic and regenerative properties of EPCs before transplantation, a more potent therapeutic strategy for postnatal neovascularization in patients with severe ischemic disease will be developed. However, strategies enhancing EPC function may not prove to be beneficial in all population groups and may even have detrimental effects, such as enhancing tumor angiogenesis. Although EPC transplantation is not currently available for patients, it is our contention that this treatment modality will come of age in the near future. Note Added in Proof During the review process, a few key advances in the field of EPC biology were made. Erythropoietin was demonstrated to enhance EPC mobilization (Heeschen et al, unpublished observations, 2003), while Assmus et al 71 showed that the beneficial effects of statins extend to the inhibition of EPC senescence and the induction of EPC proliferation. Results from Aicher et al 72 suggest that radioactive labeling may provide a useful technique for monitoring the homing of transplanted EPCs. Finally, data from our group indicate that the inflammatory marker C-reactive protein, at concentrations known to predict vascular events, potently inhibits EPC survival and differentiation (S. Verma et al, unpublished observations, 2003). Acknowledgments Supported by the Heart and Stroke Foundation of Canada and Canadian Institute for Health Research (both grants to Drs Verma and Weisel). References 1. Luttun A, Carmeliet G, Carmeliet P. Vascular progenitors: from biology to treatment. Trends Cardiovasc Med. 2002;12:88 96.
7 Szmitko et al Endothelial Progenitor Cells Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275: Bhattacharya V, McSweeney PA, Shi Q, et al. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34 bone marrow cells. Blood. 2000;95: Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodelling and improves cardiac function. Nat Med. 2001;7: Murohara T, Ikeda H, Duan J, et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest. 2000;105: Walter DH, Dimmeler S. Endothelial progenitor cells: regulation and contribution to adult neovascularization. Herz. 2002;27: Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90: Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34 cells identifies a population of functional endothelial precursors. Blood. 2000;95: Burger PE, Coetzee S, McKeehan WL, et al. Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells. Blood. 2002;100: Salven P, Mustjoki S, Alitalo R, et al. VEGFR-3 and CD133 identify a population of CD34 lymphatic/vascular endothelial precursor cells. Blood. 2003;101: Gill M, Dia S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2 AC133 endothelial precursor cells. Circ Res. 2001;88: Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:e1 e Hirschi KK, Goodell MA. Hematopoietic, vascular and cardiac fates of bone marrow-derived stem cells. Gene Ther. 2002;9: Reyes M, Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest. 2002;109: Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis and stabilization. Am J Cardiol. 2000;86:3J 9J. 16. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105: Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrowderived endothelial cells. Blood. 1998;92: Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow derived endothelial progenitor cells. Circulation. 2002;105: Werner N, Priller J, Laufs U, et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 2002;22: Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1: Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6: Kaushal S, Amiel GE, Guleserian KJ, et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med. 2001;7: Jackson KA, Majka SM, Wang H, et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest. 2001;107: Grant MB, May WS, Caballero S, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med. 2002;8: Young PP, Hofling AA, Sands MS. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc Natl Acad Sci U S A. 2002;99: Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85: Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone marrowderived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7: Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer. 2002; 2: Rafii S, Heissig B, Hattori K. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther. 2002;9: Takahashi T, Kalka C, Masuda H, et al. Ischemia and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5: Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001;103: Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18: Kalka C, Tehrani H, Laudenberg B, et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg. 2000;70: Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res. 2000;86: Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001;193: Flamme I, Breier G, Risau W. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (flk-1) are expressed during vasculogenesis and vascular differentiation in the quail embryo. Dev Biol. 1995;169: Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380: Rafii S, Meeus S, Dias S, et al. Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol. 2002;13: Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107: Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-flt1. Nat Med. 2002;8: Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1 stem cells from bone-marrow microenvironment. Nat Med. 2002;8: Bautz P, Rafii S, Kanz L, et al. Expression and secretion of vascular endothelial growth factor-a by cytokine-stimulated hematopoietic progenitor cells: possible role in the hematopoietic microenvironment. Exp Hematol. 2000;28: Seiler C, Pohl T, Wustmann K, et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation. 2001;104: Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109: Murayama T, Tepper OM, Silver M, et al. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol. 2002; 30: Pillarisetti K, Gupta SK. Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1): SDF-1 mrna is selectively induced in rat model of myocardial infarction. Inflammation. 2001;25: Mohle R, Bautz F, Rafii S, et al. The chemokine receptor CXCR-4 is expressed on CD34 hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 1998;91: Eliceiri BP, Cheresh DA. The role of v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103: Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348: Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:
8 3100 Circulation June 24, Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J Clin Invest. 2001;108: Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108: Dimmeler S, Zeiher AM. Akt takes center stage in angiogenesis signaling. Circ Res. 2000;86: Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6: Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103: Baller D, Notohamiprodjo G, Gleichmann U, et al. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation. 1999;99: Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000;97: Ikenaga S, Hamano K, Nishida M, et al. Autologous bone marrow implantation induced angiogenesis and improved deteriorated exercise capacity in a rat ischemic hindlimb model. J Surg Res. 2001;96: Shintani S, Murohara T, Ikeda H, et al. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation. 2001;103: Schatteman GC, Hanlon HD, Jiao C, et al. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest. 2000; 106: Hirata K, Li TS, Nishida M, et al. Autologous bone marrow cell implantation as therapeutic angiogenesis for ischemic hindlimb in diabetic rat model. Am J Physiol Heart Circ Physiol. 2003;284:H66 H Kawamoto A, Gwon HC, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001;103: Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 2001;104: Badorff C, Brandes RP, Popp R, et al. Transdifferentiation of bloodderived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation. 2003;107: Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone marrow cells: a pilot study and a randomized control trial. Lancet. 2002;360: Assmus B, Schachinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002;106:r53 r Strauer BE, Brehm M, Zeus T, et al. Repair of infracted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106: Nabel EG. Stem cells combined with gene transfer for therapeutic vasculogenesis: magic bullets? Circulation. 2002;105: Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation. 2002;105: Murasawa S, Llevadot J, Silver M, et al. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation. 2002;106: Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003;92: Aicher A, Brenner W, Zuhayra M, et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation. 2003;107: KEY WORDS: endothelium cells ischemia revascularization
Stem Cells. Keith Channon. Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford
Stem Cells Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford Adult Stem Cells Unique cells that are capable of self-renewal Have the ability to differentiate
More informationParacrine Mechanisms in Adult Stem Cell Signaling and Therapy
Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy Massimiliano Gnecchi, Zhiping Zhang, Aiguo Ni, Victor J. Dzau Circulation Research 2008 Nov 21;103(11):1204-19 Introduction(1) After AMI all
More informationThe vascular endothelium represents a dynamic border
Brief Review Endothelial Progenitor Cells Mobilization, Differentiation, and Homing Mihail Hristov, Wolfgang Erl, Peter C. Weber Abstract Postnatal bone marrow contains a subtype of progenitor cells that
More informationMesenchymal Stem Cells to Repair Vascular Damage after Chemotherapy: Past, Present and Future
Mesenchymal Stem Cells to Repair Vascular Damage after Chemotherapy: Past, Present and Future Cell Therapy 2014 Las Vegas, NV, USA Sulaiman Al-Hashmi, PhD Sultan Qaboos University Oman What are MSCs? Stem
More informationDiminished Circulating Monocytes after Peripheral Bypass Surgery for Critical Limb Ischemia
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 5-6-2009 Diminished Circulating Monocytes after Peripheral Bypass
More informationSignaling Vascular Morphogenesis and Maintenance
Signaling Vascular Morphogenesis and Maintenance Douglas Hanahan Science 277: 48-50, in Perspectives (1997) Blood vessels are constructed by two processes: vasculogenesis, whereby a primitive vascular
More informationCD34+ Cells: A Comparison of Stem and Progenitor Cells in Cord Blood, Peripheral Blood, and the Bone Marrow
White Paper September 2016 CD34+ Cells: A Comparison of Stem and Progenitor Cells in Cord Blood, Peripheral Blood, and the Bone Marrow Lily C. Trajman, PhD Introduction: Hematopoietic Stem Cells (HSCs)
More informationDiabetes mellitus is associated with both an increased risk
Human Endothelial Progenitor Cells From Type II Diabetics Exhibit Impaired Proliferation, Adhesion, and Incorporation Into Vascular Structures Oren M. Tepper, BA; Robert D. Galiano, MD; Jennifer M. Capla,
More informationStem cell therapy of cardiac disease: an update
Nephrol Dial Transplant (2004) 19: Editorial Comments 1673 PS analyses, the authors found that the results between these two techniques were not materially different in most of these studies. Even if the
More informationJournal Club Semmler Lorenz
Beer et al. 2015 - Analysis of the Secretome of Apoptotic Peripheral Blood Mononuclear Cells: Impact of Released Proteins and Exosomes for Tissue Regeneration Journal Club 13.11.2017 1 Introduction to
More informationCitation for published version (APA): Velde, S. V. D. (2006). Stem cell-mediated regeneration of the infarcted heart: inflammation rules? s.n.
University of Groningen Stem cell-mediated regeneration of the infarcted heart Velde, Susanne van der IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to
More informationTransplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients With Idiopathic Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 49, No. 14, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.12.037
More informationTissue renewal and Repair. Nisamanee Charoenchon, PhD Department of Pathobiology, Faculty of Science
Tissue renewal and Repair Nisamanee Charoenchon, PhD Email: nisamanee.cha@mahidol.ac.th Department of Pathobiology, Faculty of Science Topic Objectives 1. Describe processes of tissue repair, regeneration
More informationProfessor Harvey White. Interventional Cardiologist Auckland
Professor Harvey White Interventional Cardiologist Auckland Stem cells and the heart Harvey White Director of Coronary Care Unit and Cardiovascular Research Unit Green Lane Cardiovascular Service Auckland
More informationTissue repair. (3&4 of 4)
Tissue repair (3&4 of 4) What will we discuss today: Regeneration in tissue repair Scar formation Cutaneous wound healing Pathologic aspects of repair Regeneration in tissue repair Labile tissues rapid
More informationResident cardiac stem cells: how to find and use them
Resident cardiac stem cells: how to find and use them G. Hasenfuß Cardiology and Pneumology Heart Research Center Göttingen Georg-August-University Göttingen Definition: Stem cell Selfrenewal Stem cell
More informationFinancial Disclosures. Bone Marrow Mononuclear Cells. Cell Based Therapies: What Do They Do and Will They Work in CLI?
Cell Based Therapies: What Do They Do and Will They Work in CLI? None Financial Disclosures Michael P. Murphy, MD The Vascular and Cardiac Adult Stem Cell Therapy Center Indiana University School of Medicine
More informationZachary I. Hodes, M.D., Ph.D., F.A.C.C.
Zachary I. Hodes, M.D., Ph.D., F.A.C.C. Disclamer: I personally have no financial relationship with any company mentioned today. The Care Group, LLC does have a contract with Cardium to participate in
More informationCirculating Endothelial Progenitor Cells and Cardiovascular Outcomes
original article Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes Nikos Werner, M.D., Sonja Kosiol, M.D., Tobias Schiegl, M.D., Patrick Ahlers, M.D., Katrin Walenta, M.D., Andreas Link,
More informationStem cells and progenitor cells in renal disease
Kidney International, Vol. 68 (2005), pp. 1932 1936 Stem cells and progenitor cells in renal disease HERMANN HALLER,KIRSTEN DE GROOT,FERDINAND BAHLMANN, MARLIES ELGER, and DANILO FLISER Department of Nephrology,
More informationStatin Therapy Accelerates Reendothelialization
Statin Therapy Accelerates Reendothelialization A Novel Effect Involving Mobilization and Incorporation of Bone Marrow Derived Endothelial Progenitor Cells Dirk H. Walter, MD; Kilian Rittig, MD; Ferdinand
More informationNo option-patients : Is angiogenesis with gene or cell therapy still an option?
No option-patients : Is angiogenesis with gene or cell therapy still an option? Professor Sigrid Nikol Clinical and Interventional Angiology Asklepios-Klinik St. Georg Hamburg, Germany Angiogenic gene
More informationHaematopoietic stem cells
Haematopoietic stem cells Neil P. Rodrigues, DPhil NIH Centre for Biomedical Research Excellence in Stem Cell Biology Boston University School of Medicine neil.rodrigues@imm.ox.ac.uk Haematopoiesis: An
More informationSynergistic Effect of Bone Marrow Mobilization and Vascular Endothelial Growth Factor-2 Gene Therapy in Myocardial Ischemia
Synergistic Effect of Bone Marrow Mobilization and Vascular Endothelial Growth Factor-2 Gene Therapy in Myocardial Ischemia Atsuhiko Kawamoto, MD, PhD*; Toshinori Murayama, MD, PhD*; Kengo Kusano, MD,
More informationSupplemental Table 1 Clinical trials of cell-based cardiac repair without controls or with nonrandomized study design
Cell-Based Therapy for Myocar Ischemia and Infarction: Pathophysiological Mechanisms Supplemental Table 1 Clinical trials of cell-based cardiac repair without s or with nonrandom study design Head-tohead
More informationProtocol. Progenitor Cell Therapy for the Treatment of Damaged Myocardium due to Ischemia
(20218) Medical Benefit Effective Date: 01/01/11 Next Review Date: 07/18 Preauthorization No Review Dates: 09/10, 07/11, 07/12, 07/13, 07/14, 07/15, 07/16, 07/17 This protocol considers this test or procedure
More informationPrevious studies from our laboratory 1 6 and others 7 13 have
Basic Science Reports Endothelial Progenitor Cell Vascular Endothelial Growth Factor Gene Transfer for Vascular Regeneration Hideki Iwaguro, MD; Jun-ichi Yamaguchi, MD, PhD; Christoph Kalka, MD; Satoshi
More informationTherapeutic Angiogenesis: The Pros and Cons and the Future
REVIEW Korean Circ J 2008;38:73-79 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2008 The Korean Society of Cardiology Therapeutic Angiogenesis: The Pros and Cons and the Future Jae Kean Ryu,
More informationEndothelial progenitor cells (EPCs) are
Separation and identification of endothelial progenitor cells from rat peripheral blood Si-Lin Pan, Quan-Sheng Xing, Long Sun Qingdao, China 50 Background: Kawasaki disease (KD) as the most commonly acquired
More informationUnderstanding the Role of Endothelial Progenitor Cells in Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 55, No. 15, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.070
More informationDevices are So Old School: The New World of Myocardial Regeneration
Devices are So Old School: The New World of Myocardial Regeneration Todd K. Rosengart, M.D. Professor and Chairman DeBakey-Bard Chair of Surgery Michael E. DeBakey Department of Surgery Professor, Texas
More informationThe concept of regenerative medicine using the body s
MINI-REVIEW: EXPERT OPINIONS Stem Cell Therapy in Perspective Bodo E. Strauer, MD; Ran Kornowski, MD The concept of regenerative medicine using the body s own stem cells and growth factors to repair tissues
More informationSurgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study
Patel et al Evolving Technology Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study Amit N. Patel, MD, MS, a,b,c Luis Geffner,
More informationEndothelial Injury and Repair as a Working Paradigm
Endothelial Injury and Repair as a Working Paradigm A. Linke ESC Meeting 2010 UNIVERSITÄTLEIPZIG H ERZZEN TRUM Physiology of Endothelial Function: Regulation of Vascular Tone L-Arg. L-Arg. Agonists Shear
More informationReviews. This Review is part of a thematic series on Cellular Therapy, which includes the following articles:
Reviews This Review is part of a thematic series on Cellular Therapy, which includes the following articles: The Stem Cell Movement Genetic Enhancement of Stem Cell Engraftment, Survival, and Efficacy
More informationThe Number of Endothelial Progenitor Cell Colonies in the Blood Is Increased in Patients With Angiographically Significant Coronary Artery Disease
Journal of the American College of Cardiology Vol. 48, No. 8, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.04.101
More informationPathology of Cardiovascular Interventions. Body and Disease 2011
Pathology of Cardiovascular Interventions Body and Disease 2011 Coronary Artery Atherosclerosis Intervention Goals: Acute Coronary Syndromes: Treat plaque rupture and thrombosis Significant Disease: Prevent
More informationAutologous Bone Marrow Mononuclear Cells Transplant in Patients With Critical Leg Ischemia: Preliminary Clinical Results
ARTIcle Autologous Bone Marrow Mononuclear Cells Transplant in Patients With Critical Leg Ischemia: Preliminary Clinical Results Min Li, 1 Hua Zhou, 2 Xing Jin, 2 Mo Wang, 2 Shiyi Zhang, 2 Lei Xu 2 Abstract
More informationVascular injury leads to pathological repair and remodeling
Cytokine-Induced Mobilization of Circulating Endothelial Progenitor Cells Enhances Repair of Injured Arteries Deling Kong, PhD; Luis G. Melo, PhD; Massimiliano Gnecchi, MD; Lunan Zhang, MD; Gustavo Mostoslavsky,
More informationThe postnatal growth of new blood vessels results from 2
Vascular Medicine Secretoneurin, an Angiogenic Neuropeptide, Induces Postnatal Vasculogenesis Rudolf Kirchmair, MD; Margot Egger; Dirk H. Walter, MD; Wolfgang Eisterer, MD; Andreas Niederwanger, MD; Ewald
More informationThere was a report about endothelial progenitor cells
Characterization of Two Types of Endothelial Progenitor Cells and Their Different Contributions to Neovasculogenesis Jin Hur, Chang-Hwan Yoon, Hyo-Soo Kim, Jin-Ho Choi, Hyun-Jae Kang, Kyung-Kook Hwang,
More informationUse of Adipose-Derived Stem Cells in Regenerative Therapy. David Euhus, MD Professor of Surgery UT Southwestern Medical Center at Dallas
Use of Adipose-Derived Stem Cells in Regenerative Therapy David Euhus, MD Professor of Surgery UT Southwestern Medical Center at Dallas Use of Adipose-Derived Stem Cells in Regenerative Therapy David Euhus,
More informationReprogramming through micrornas Stefanie Dimmeler
Klinikum der Johann Wolfgang Goethe Universität Frankfurt am Main Reprogramming through micrornas Stefanie Dimmeler Conflict of interest: T2cure GmbH, Miragen Non-coding DNA & RNA and micrornas Human Genome
More informationGrowth-factor-induced mobilisation of stem cells after acute infarction: which growth factors and when?
Growth-factor-induced mobilisation of stem cells after acute infarction: which growth factors and when? Giulio Pompilio MD PhD DEPT. OF CARDIOVASCULAR SURGERY LABORATORY OF VASCULAR BIOLOGY AND REGENERATIVE
More informationStrategic Research Development in Stem Cell and Regenerative Medicine in HKU Professor Sum-ping Lee Dean HKU Li Ka Shing Faculty of Medicine
Strategic Research Development in Stem Cell and Regenerative Medicine in HKU Professor Sum-ping Lee Dean HKU Li Ka Shing Faculty of Medicine Adult stem cells Cells that are capable of self renewal and
More informationCirculating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk
The new england journal of medicine original article Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk Jonathan M. Hill, M.R.C.P., Gloria Zalos, R.N., Julian P.J. Halcox,
More informationOptimization of Generx (Ad5FGF-4) Clinical Trial Design for Refractory Angina: Interim Results of the Phase 3 ASPIRE Trial
Optimization of Generx (Ad5FGF-4) Clinical Trial Design for Refractory Angina: Interim Results of the Phase 3 ASPIRE Trial Gabor M Rubanyi, MD. PhD. Angionetics Inc., San Diego, CA ASGCT, New Orleans,
More informationPhD THESIS FACTORS MODULATING THE THERAPEUTIC POTENTIAL OF ENDOTHELIAL PROGENITOR CELLS FOR NEOVASCULARIZATION OF ISCHEMIC TISSUES
ROMANIAN ACADEMY INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY "NICOLAE SIMIONESCU" PhD THESIS FACTORS MODULATING THE THERAPEUTIC POTENTIAL OF ENDOTHELIAL PROGENITOR CELLS FOR NEOVASCULARIZATION OF ISCHEMIC
More informationDECLARATION OF CONFLICT OF INTEREST. No disclosures
DECLARATION OF CONFLICT OF INTEREST No disclosures micrornas: Role in progression of atherosclerosis Christian Weber Institute for Cardiovascular Prevention (IPEK) Ludwig-Maximilians-University Munich
More informationIliac Crest: The Gold Standard
Iliac Crest: The Gold Standard Iliac crest is often considered the gold standard for harvesting. The iliac crest contains bone marrow which is a rich source of regenerative cells, including: Endothelial
More informationStem Cell Therapy Concept. Pleuripotent Stromal Cells 8/8/2011. Use of Adipose-Derived Stem Cells in Regenerative Therapy
Use of Adipose-Derived Stem Cells in Regenerative Therapy Use of Adipose-Derived Stem Cells in Regenerative Therapy David Euhus, MD Professor of Surgery UT Southwestern Medical Center at Dallas David Euhus,
More informationCurrent developments in the use of stem cell for therapeutic neovascularisation: is the future therapy cell-free?
Published 17 December 2010, doi:10.4414/smw.2010.13130 Cite this as: Current developments in the use of stem cell for therapeutic neovascularisation: is the future therapy cell-free? Zijiang Yang a, Stefano
More informationPhD THESIS Epigenetic mechanisms involved in stem cell differentiation
Romanian Academy Institute of Cellular Biology and Pathology "Nicolae Simionescu" PhD THESIS Epigenetic mechanisms involved in stem cell differentiation Coordinator: Acad. Maya Simionescu PhD Student:
More informationHMG-CoA reductase inhibitor mobilizes bone marrow derived endothelial progenitor cells
HMG-CoA reductase inhibitor mobilizes bone marrow derived endothelial progenitor cells See related Commentary on pages 365 366. Joan Llevadot, 1 Satoshi Murasawa, 1 Yasuko Kureishi, 1 Shigeki Uchida, 1
More informationREVIEW Hematopoietic, vascular and cardiac fates of bone marrow-derived stem cells
(2002) 9, 648 652 2002 Nature Publishing Group All rights reserved 0969-7128/02 $25.00 www.nature.com/gt REVIEW Hematopoietic, vascular and cardiac fates of bone marrow-derived stem cells KK Hirschi 1
More informationSDF-1/CXCR4 Axis on Endothelial Progenitor Cells Regulates Bone Fracture Healing
SDF-1/CXCR4 Axis on Endothelial Progenitor Cells Regulates Bone Fracture Healing Yohei Kawakami, M.D., Ph.D. 1,2, Masaaki Ii 3, Tomoyuki Matsumoto, M.D., Ph.D. 1, Astuhiko Kawamoto, M.D., Ph.D. 2, Yutaka
More informationConflict of Interest Slide
Comparison of six- month clinical outcomes, event free survival rates of patients undergoing enhanced external counterpulsation (EECP) for coronary artery disease in the United States and Europe Ozlem
More informationENDOTHELIAL PROGENITOR CELLS AS A NOVEL BIOMARKER OF VASCULAR HEALTH
ENDOTHELIAL PROGENITOR CELLS AS A NOVEL BIOMARKER OF VASCULAR HEALTH I Jialal, MD, PhD. FRCPath.DABCC Robert E. Stowell Chair in Experimental Pathology Professor of Pathology and Medicine Director, Laboratory
More informationREGENERATIVE MEDICINE
REGENERATIVE MEDICINE Concise Review: Circulating Endothelial Progenitor Cells for Vascular Medicine TAKAYUKI ASAHARA, a,b ATSUHIKO KAWAMOTO, b HARUCHIKA MASUDA a a Department of Regenerative Medicine
More informationCell implantation after myocardial infarction: a 10 years experience from the ICREC laboratory
Cell implantation after myocardial infarction: a 10 years experience from the ICREC laboratory BANFF-SCT Joint Scientific Meeting 2017 Barcelona, 29 th March Santi Roura, PhD Grup ICREC IGTP HuGTiP (Badalona)
More informationCell therapy: enhancing the therapeutic potential of cardiac progenitors for delivery post myocardial infarction. Rita Alonaizan
Cell therapy: enhancing the therapeutic potential of cardiac progenitors for delivery post myocardial infarction Rita Alonaizan Department of Physiology, Anatomy & Genetics St Catherine s College Supervisor:
More informationChapter 6. Villous Growth
Core Curriculum in Perinatal Pathology Chapter 6 Villous Growth Overview of vasculogenesis and angiogenesis Vasculogenesis Extraembryonic Vasculogenesis Angiogenesis Branching angiogenesis Sprouting angiogenesis
More informationFibronectin promotes VEGF-induced CD34 cell differentiation into endothelial cells
Fibronectin promotes VEGF-induced CD34 cell differentiation into endothelial cells Errol S. Wijelath, PhD, a Salman Rahman, PhD, b Jacqueline Murray, PhD, a Yatin Patel, PhD, b Geoffrey Savidge, MD, b
More informationA mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy
NEOPLASIA A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy Brian R. Stoll, Cristiano Migliorini, Ananth Kadambi,
More informationRegenerative Medicine for Cardiomyocytes
Regenerative Medicine Regenerative Medicine for JMAJ 47(7): 328 332, 2004 Keiichi FUKUDA Assistant Professor, Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine Abstract: Heart
More informationDr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK
Advanced heart failure - devices, mechanical circulatory support and cardiac transplantation Monday 30 January 2017 Stem cell and gene therapies for heart failure Dr. Alexander Lyon Senior Lecturer and
More informationENDOGENOUS CARDIAC STEM CELLS IN THE REGENERATION OF ACUTE AND CHRONIC ISCHEMIC MYOCARDIUM
ENDOGENOUS CARDIAC STEM CELLS IN THE REGENERATION OF ACUTE AND CHRONIC ISCHEMIC MYOCARDIUM Bernardo Nadal-Ginard, M.D., Ph.D. New York Medical College Angioplasty Summit 2004, Seoul 04/29/04 MYOCARDIAL
More informationMesenchymal Stem Cells
Mesenchymal Stem Cells Science and therapeutic applications Dirk Büscher (Former VP-R&D Cellerix) GRIFOLS SA May 10 th, 2010 EMA 1 Discovery and Definition of Mesenchymal Stem Cells MSC must be plastic-adherent
More informationDOWNLOAD PDF CARDIAC REMODELING AND CELL DEATH IN HEART FAILURE
Chapter 1 : The fibrosis-cell death axis in heart failure Remodeling may be defined as changes in the morphology, structure, and function of the heart related to alterations in loading conditions and/or
More informationTopic: Stem-cell Therapy for Peripheral Arterial Disease Date of Origin: September 29, Section: Medicine Last Reviewed Date: October 2013
Medical Policy Manual Topic: Stem-cell Therapy for Peripheral Arterial Disease Date of Origin: September 29, 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No: 141 Effective Date: January
More informationAngiogenesis in Human Development. Vascular Development
Angiogenesis in Human Development Jan Kitajewski ICRC 217B, ph 851-4688, email: jkk9 BACKGROUND READING: Vascular Development Signaling Vascular Morphogenesis and Maintenance Douglas Hanahan. Science 277:
More informationThe role of bone marrow-derived endothelial progenitor cells and angiogenic responses in chronic obstructive pulmonary disease
Review Article The role of bone marrow-derived endothelial progenitor cells and angiogenic responses in chronic obstructive pulmonary disease Brittany Salter, Roma Sehmi CardioRespiratory Research Group,
More informationEndothelial Progenitor Cell Dysfunction: a Novel Concept in the Pathogenesis of Vascular Complications of Type 1 Diabetes
Chapter3 Endothelial Progenitor Cell Dysfunction: a Novel Concept in the Pathogenesis of Vascular Complications of Type 1 Diabetes Cindy J.M. Loomans 1, Eelco J.P. de Koning 1, Frank J.T. Staal 2, Maarten
More informationMedical Coverage Policy Progenitor Cell Therapy for the Treatment of Damaged Myocardium due to Ischemia
Medical Coverage Policy Progenitor Cell Therapy for the Treatment of Damaged Myocardium due to Ischemia EFFECTIVE DATE: 02 01 2017 POLICY LAST UPDATED: 02 20 2018 OVERVIEW Progenitor cell therapy describes
More informationGENE THERAPY IN CARDIOVASCULAR DISEASES ASAN MEDICAL CENTER KI HOON HAN MD
GENE THERAPY IN CARDIOVASCULAR DISEASES ASAN MEDICAL CENTER KI HOON HAN MD GENE THERAPY 1. CORRECT GENES 2. CURE WITH GENES WHAT IS GENE? DNA ( deoxyribonucleic acid ) - DOUBLE HELICAL STRUCTURE GENE ;
More informationProtocol. Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia
(20218) Medical Benefit Effective Date: 01/01/11 Next Review Date: 07/15 Preauthorization No Review Dates: 09/10, 07/11, 07/12, 07/13, 07/14 The following Protocol contains medical necessity criteria that
More informationRole of Inflammation in Pulmonary Hypertension
Role of Inflammation in Pulmonary Hypertension K. R. Stenmark University of Colorado Denver, USA Prominent Fibroproliferative Changes are Observed in the Lung Vasculature of Infants With Pulmonary Arterial
More informationAutologous bone marrow stem cell transplantation,
Tissue Distribution of F-FDG-Labeled Peripheral Hematopoietic Stem Cells After Intracoronary Administration in Patients with Myocardial Infarction Won Jun Kang 1, Hyun-Jae Kang 2, Hyo-Soo Kim 2, June-Key
More informationHematopoiesis. - Process of generation of mature blood cells. - Daily turnover of blood cells (70 kg human)
Hematopoiesis - Process of generation of mature blood cells - Daily turnover of blood cells (70 kg human) 1,000,000,000,000 total cells 200,000,000,000 red blood cells 70,000,000,000 neutrophils Hematopoiesis
More informationrenoprotection therapy goals 208, 209
Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization
More informationMultimodality Imaging in Cardiac Stem Cell Research
Multimodality Imaging in Cardiac Stem Cell Research IL SUK SOHN, MD, PhD Department of Cardiology Kyung Hee University Hospital at Gangdong Kyung Hee University School of Medicine, Seoul, Korea Stem Cell
More informationWIEF-AFF ROUNDTABLE Tokyo, Japan 26 May 2015
WIEF-AFF ROUNDTABLE 2015 Tokyo, Japan 26 May 2015 Regenerative Medicine Goal: - To restore organ +/- tissue function - For pts with serious injuries or chronic disease where the body unable to heal & restore
More informationCorporate Medical Policy
Corporate Medical Policy Stem-cell Therapy for Peripheral Arterial Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: stem_cell_therapy_for_peripheral_arterial_disease 7/2011
More informationMeeting Report. From December 8 to 11, 2012 at Atlanta, GA, U.S.A
Meeting Report Affiliation Department of Transfusion Medicine and Cell Therapy Name Hisayuki Yao Name of the meeting Period and venue Type of your presentation Title of your presentation The 54 th Annual
More informationThe Promise of Cell-Based Therapies for Diabetic Complications: Challenges and Solutions
This article is part of a thematic series on Cardiovascular Complications of Diabetes and Obesity which includes the following articles: The Impact of Macrophage Insulin Resistance on Advanced Atherosclerotic
More informationTranscoronary Transplantation of Progenitor Cells after Myocardial Infarction
The new england journal of medicine original article Transcoronary Transplantation of Progenitor Cells after Myocardial Infarction Birgit Assmus, M.D., Jörg Honold, M.D., Volker Schächinger, M.D., Martina
More informationStatins and endothelium function
Statins and endothelium function Matthias Endres Berlin, Germany Klinik und Poliklinik für Neurologie Conflict of interest: research grant from AstraZeneca from prevention to acute therapy... Pleiotropic
More informationChapter 6: Summary
Chapter 6: Summary The present thesis describes several clinical studies on the topic of intravenous myocardial contrast echocardiography, and an experimental study on the effect of ultrasound contrast
More informationProgenitor cells circulate in the bloodstream, with the
Granulocyte Colony-Stimulating Factor Mobilizes Functional Endothelial Progenitor Cells in Patients With Coronary Artery Disease Tiffany M. Powell, Jonathan D. Paul, Jonathan M. Hill, Michael Thompson,
More informationRole of Inflammatory and Progenitor Cells in Pulmonary Vascular Remodeling: Potential Role for Targeted Therapies. Traditional Hypothesis Stress
3/1/212 Role of Inflammatory and Progenitor Cells in Pulmonary Vascular Remodeling: Potential Role for Targeted Therapies K.R. Stenmark University of Colorado Denver, CO 845 Prominent Fibroproliferative
More informationAutologous Peripheral Blood Mononuclear Cell Implantation for Patients With Peripheral Arterial Disease Improves Limb Ischemia
Circ J 2005; 69: 1260 1265 Autologous Peripheral Blood Mononuclear Cell Implantation for Patients With Peripheral Arterial Disease Improves Limb Ischemia Akio Ishida, MD; Yusuke Ohya, MD; Hitoshi Sakuda,
More informationLeading the Way in Cardiovascular Regenerative Medicine
Slide 1 Leading the Way in Cardiovascular Regenerative Medicine Leading the Way in Cardiovascular Regenerative Medicine This slide set presents the current work in cell therapy in treating cardiovascular
More informationSeveral bone marrow subpopulations, such as endothelial
Local Delivery of Marrow-Derived Stromal Cells Augments Collateral Perfusion Through Paracrine Mechanisms T. Kinnaird, MBBCh; E. Stabile, MD; M.S. Burnett, PhD; M. Shou, MD; C.W. Lee, MD; S. Barr, MBBCh;
More informationStem cell related, postnatal neovascularization requires
Pivotal Role of Lnk Adaptor Protein in Endothelial Progenitor Cell Biology for Vascular Regeneration Sang-Mo Kwon,* Takahiro Suzuki,* Atsuhiko Kawamoto, Masaaki Ii, Masamichi Eguchi, Hiroshi Akimaru, Mika
More informationMesenchymal Stem Cells and Cancer: Their Interplay
Mesenchymal Stem Cells and Cancer: Their Interplay Gang Li, MBBS, DPhil (Oxon) Stem Cell and Regeneration Program School of Biomedical Sciences Li Ka Shing Institute of Health Sciences Department of Orthopaedics
More informationPathology of Coronary Artery Disease
Pathology of Coronary Artery Disease Seth J. Kligerman, MD Pathology of Coronary Artery Disease Seth Kligerman, MD Assistant Professor Medical Director of MRI University of Maryland Department of Radiology
More informationEndothelial PGC 1 - α 1 mediates vascular dysfunction in diabetes
Endothelial PGC-1α mediates vascular dysfunction in diabetes Reporter: Yaqi Zhou Date: 04/14/2014 Outline I. Introduction II. Research route & Results III. Summary Diabetes the Epidemic of the 21st Century
More information115 Endothelial Progenitor Cells: A Novel Laboratory-Based Biomarker of Vascular Health. Ishwarlal Jialal
115 Endothelial Progenitor Cells: A Novel Laboratory-Based Biomarker of Vascular Health Ishwarlal Jialal 211 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 33 W. Monroe, Ste. 16 Chicago,
More informationAccepted Manuscript. Late venous graft failure: mystery solved? Siamak Mohammadi, MD, FRCSC, Dimitri Kalavrouziotis, MD, FRCSC
Accepted Manuscript Late venous graft failure: mystery solved? Siamak Mohammadi, MD, FRCSC, Dimitri Kalavrouziotis, MD, FRCSC PII: S0022-5223(18)32542-X DOI: 10.1016/j.jtcvs.2018.09.038 Reference: YMTC
More information